Skip to search formSkip to main contentSkip to account menu

1.2 ML Plerixafor 20 MG/ML Injection [Mozobil]

Known as: Mozobil 24 MG in 1.2 ML Injection, Mozobil 24 MG per 1.2 ML Injection, PLERIXAFOR 24 mg in 1.2 mL SUBCUTANEOUS SOLUTION [Mozobil] 
National Institutes of Health

Related topics

Related topics

8 relations
Hydrochloric AcidInjectionMozobilPlerixafor

Broader (1)

Plerixafor Injection [Mozobil]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018
ABSTRACT Introduction: The chemokine receptor CXCR4 has been under intense study due to the central role it plays in immune… 
2018
2018
Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes.
2016
2016
The interaction of Mozobil™ with carboxylates.
Mozobil(™) (1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane], 1, also known as JM3100 and AMD 3100) is a… 
2012
2012
Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience
Chronic lymphocytic leukemia (CLL) cells express high levels of CXCR4, a seven transmembrane G-protein coupled chemokine receptor… 
2010
2010
Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma
Patients suffering from hematological malignancies such as Non Hodgkin’s Lymphoma, Hodgkin Lymphoma or Multiple Myeloma are… 
Review
2010
Review
2010
Plerixafor (Mozobil®) en pacients amb limfoma i mieloma múltiple
Limfoma; Mieloma multiple; Revisio sistematica; Lymphoma; Multiple Myeloma; Systematic review; Linfoma; Revision sistematica 
2010
2010
Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Pediatric Patients with Malignant Disorders
Abstract 2245 Background: High dose chemo/radiotherapy followed by autologous hematopoietic stem cell (HSC) transplantation (HSCT… 
2009
2009
Mobilization with Plerixafor (Mozobil ®)Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in…
Abstract 3224 Poster Board III-161 Background While most centers use 2 × 10 6 CD34+ cells/kg as the minimal cell dose for… 
2009
2009
Plerixafor (Mozobil ®)Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Abstract 3229 Poster Board III-166 Introduction Low platelet count prior to mobilization is a significant predictive factor for… 
2009
2009
Plerixafor (Mozobil®) Selectively Enhances Donor Hematopoietic Cell Engraftment.
Abstract 368 Introduction: Reducing transplant-related mortality and facilitating donor engraftment are very important goals in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)